Logo

NXGLW

NEXGEL, Inc.

NXGLW

NEXGEL, Inc. • NASDAQ
$0.20 ▲ 18.29% (+0.03)
Market Cap $15.59 M
52w High $0.31
52w Low $0.16
Dividend Yield 0%
P/E -0.14
Volume 15.66K
Outstanding Shares 72.42M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $2.934M ▲ $1.968M ▲ $-653K ▲ -22.256% ▲ $-0.08 ▲ $-524K ▼
Q2-2025 $2.884M ▲ $1.894M ▼ $-665K ▲ -23.058% ▲ $-0.087 ▲ $-520K ▲
Q1-2025 $2.806M ▼ $1.965M ▲ $-712K ▲ -25.374% ▲ $-0.093 ▲ $-531K ▲
Q4-2024 $3.041M ▲ $1.62M ▼ $-850K ▼ -27.951% ▼ $-0.12 ▼ $-660K ▼
Q3-2024 $2.94M $2.07M $-693K -23.571% $-0.11 $-550K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $938K ▲ $11.62M ▲ $6.044M ▲ $5.186M ▲
Q2-2025 $725K ▼ $9.711M ▼ $4.656M ▼ $4.671M ▼
Q1-2025 $1.192M ▼ $10.437M ▼ $4.869M ▼ $5.209M ▼
Q4-2024 $1.807M ▲ $10.983M ▲ $4.903M ▼ $5.755M ▲
Q3-2024 $1.059M $10.572M $5.586M $4.687M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-653K ▲ $-785K ▼ $-8K ▲ $1.926M ▲ $1.133M ▲ $-793K ▼
Q2-2025 $-665K ▲ $-407K ▼ $-20K ▼ $-40K ▲ $-467K ▲ $-427K ▼
Q1-2025 $-712K ▲ $-400K ▲ $0 ▲ $-215K ▼ $-615K ▼ $-400K ▲
Q4-2024 $-850K ▼ $-859K ▲ $-63K ▼ $1.67M ▲ $748K ▲ $-928K ▲
Q3-2024 $-693K $-1.216M $-8K $1.214M $-10K $-1.229M

Revenue by Products

Product Q2-2024Q4-2024Q1-2025Q2-2025
Contract Manufacturing
Contract Manufacturing
 $0 ▲$0 ▲$0 ▲$0 ▲
Other Incomes
Other Incomes
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement NEXGEL looks like an early‑stage company where the business story is far ahead of the financials. Reported revenue in the dataset is essentially negligible, and the company continues to post losses per share year after year. There are some signs that losses per share have narrowed a bit more recently, but this is still clearly a company investing for growth rather than one that is financially mature or consistently profitable. The income statement profile is typical of a small, developing healthcare technology business that has not yet converted its pipeline and partnerships into meaningful, steady sales and earnings.

Balance Sheet

Balance Sheet The balance sheet appears very small and simple. Asset and equity levels are thin, and cash on hand looks limited in the data provided, although the company carries essentially no financial debt. This means the business is not weighed down by interest payments, but it also signals a narrow financial cushion. NEXGEL’s ability to fund operations and growth will likely depend heavily on continued access to outside capital until its own cash generation improves. Overall, the balance sheet shows a lean, lightly leveraged company with modest resources and limited room for financial missteps.

Cash Flow

Cash Flow The cash flow profile, based on the data shown, does not yet demonstrate clear, positive cash generation from operations. Capital spending requirements appear light, which helps, but the main issue is that the underlying business is not yet throwing off cash. This suggests NEXGEL is still in a build‑out and commercialization phase, where outflows to support R&D, manufacturing, and commercial partnerships outweigh inflows from customers. Sustainability over time will depend on either a ramp‑up in revenues, continued external financing, or both.

Competitive Edge

Competitive Edge Competitively, NEXGEL is a niche player in a very large medical and consumer products landscape. Its strength lies in a specialized hydrogel platform, in‑house US manufacturing, and a library of customized formulations. The company has secured relationships with large, well‑known healthcare and consumer brands, which provides outside validation, distribution access, and potential revenue scale that it could not achieve alone. At the same time, NEXGEL is tiny compared with global giants in wound care and medical supplies, so it competes by being flexible, specialized, and partner‑friendly rather than by size. Its position is promising in targeted niches but still unproven at large scale, and it is highly dependent on successful execution with its larger partners.

Innovation and R&D

Innovation and R&D Innovation is clearly the core of the NEXGEL story. The company has developed a broad set of hydrogel formulations tailored for different uses—from advanced wound dressings and medical patches to beauty products and consumer relief patches. Its electron beam cross‑linking process and high‑water-content gels give it a differentiated technology platform that can be adapted for many applications and brands, including white‑label products for partners. The pipeline includes new products and geographic expansion, such as scar and stretch‑mark solutions and additional wound care approvals. The key question is less about technical capability and more about commercial scaling: how quickly and efficiently these innovations can be turned into recurring, profitable product lines.

Summary

Overall, NEXGEL is a very small, early‑stage healthcare technology company with an interesting, specialized product platform but still‑immature financials. The technology and partnership story—hydrogel expertise, in‑house manufacturing, and collaborations with large pharmaceutical and consumer health companies—is the clear strength. The main risks are financial scale, continued losses, a thin capital base, and reliance on partners to turn technical wins into sustainable revenue streams. Key factors to monitor going forward include the pace of revenue growth from existing and new partnerships, improvement in margins and cash generation, evidence of repeat demand for its branded and white‑label products, and how the company manages funding needs while it works toward a more self‑sustaining business model.